文献速递糖尿病

穿孔素药理抑制减轻小鼠自身免疫性糖尿病中CD8⁺T细胞介导的β细胞破坏

Pharmacological inhibition of perforin dampens CD8+ T cell-mediated beta cell destruction in autoimmune diabetes in mice.
PubMed 文献 · Diabetologia · 2026-06-11

该研究评估小分子穿孔素抑制剂SN34960在非肥胖糖尿病(NOD)小鼠中保护β细胞免受自身反应性CD8⁺T细胞攻击的能力。体外实验中SN34960保护胰岛免受CD8⁺T细胞破坏(p<0.001);体内单次给药使IGRP肽负载靶细胞死亡减少约50%(p<0.05);7天治疗使抗PDL1阻断加速自身免疫攻击时的糖尿病发生率从91.2%降至58.4%(p<0.05)。结论提示穿孔素药理抑制可能成为保护β细胞的新策略。

要点

  • SN34960在体外保护胰岛免受CD8⁺T细胞介导的破坏(p<0.001)。
  • 单次SN34960使IGRP肽负载靶细胞16小时内死亡减少约50%(p<0.05)。
  • 7天SN34960治疗使抗PDL1加速模型糖尿病发生率91.2% vs 58.4%(p<0.05)。

核心结论

  • 药理抑制穿孔素可能代表一种保护β细胞免受自身反应性CD8⁺T细胞破坏的新方法。

研究设计与样本

  • 研究评估新型小分子穿孔素抑制剂SN34960在非肥胖糖尿病(NOD)小鼠中体外和体内保护β细胞的能力。

主要发现

  • 体外,SN34960保护分离的胰岛免受CD8⁺T细胞介导的破坏(p<0.001)。
  • 体内,单次剂量SN34960使IGRP肽负载靶细胞16小时内死亡较非肽负载对照细胞减少约50%(p<0.05)。
  • 7天穿孔素抑制剂治疗的糖尿病前期NOD小鼠在抗PDL1阻断加速自身免疫攻击时糖尿病发生率降低(91.2% vs 58.4%,p<0.05)。
  • SN34960不改变浸润胰腺的致病性细胞毒性T淋巴细胞的活化或分化状态,而是特异性阻断穿孔素分泌后的膜破坏和促凋亡效应。

临床怎么用

  • 穿孔素药理抑制可能作为保护β细胞、减缓自身免疫糖尿病进展的新策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: CD8⁺ T cells are key mediators of beta cell destruction in type 1 diabetes, employing the perforin/granzyme and Fas/Fas ligand pathways. Evidence from our studies and others indicates that perforin plays a dominant role in CD8⁺ T cell mediated beta cell destruction in non-obese diabetic (NOD) mice. As perforin is indispensable for delivering pro-apoptotic granzymes into the cytosol of target cells, pharmacological inhibition of perforin may potentially protect beta cells against CD8+ T cell cytotoxicity. Such a strategy will slow down beta cell loss and the progression to autoimmune diabetes. Small molecule perforin inhibitors recently becoming available provided an opportunity to test this hypothesis. METHODS: The new small molecule perforin inhibitor SN34960 was evaluated for its ability to protect the beta cells of non-obese diabetic mice upon attack by autoreactive cytotoxic T lymphocytes, both in vitro and in vivo. RESULTS: In vitro, perforin inhibitor SN34960 protected isolated pancreatic islets from CD8+ T cell-mediated destruction (p<0.001). In vivo, a single dose of SN34960 reduced the death of islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP) peptide-loaded target cells by ~50% over 16 h compared with non-peptide-loaded control cells (p<0.05). Furthermore, prediabetic NOD mice treated with perforin inhibitor for 7 days had a reduced incidence of diabetes when autoimmune attack was accelerated by anti-PDL1 blockade (91.2% vs 58.4%, p<0.05). Pharmacological perforin inhibition with SN34960 did not alter the activation or differentiation status of pathogenic cytotoxic T lymphocyte infiltrating the pancreas; instead, its mode of action is specifically to block the membrane-disruptive and pro-apoptotic effects of perforin following its secretion into the synaptic cleft. CONCLUSIONS/INTERPRETATION: Our results suggest that pharmacological perforin inhibition may represent a novel approach to protect beta cells from destruction by autoreactive CD8+ T cells.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Trivedi PM, Catterall T, Sutton VR, et al. Pharmacological inhibition of perforin dampens CD8+ T cell-mediated beta cell destruction in autoimmune diabetes in mice. Diabetologia. 2026. PMID: 42277401. doi:10.1007/s00125-026-06773-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。